INVELTYS Drug Patent Profile
✉ Email this page to a colleague
When do Inveltys patents expire, and when can generic versions of Inveltys launch?
Inveltys is a drug marketed by Alcon Labs Inc and is included in one NDA. There are twelve patents protecting this drug.
This drug has eighty-four patent family members in twelve countries.
The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inveltys
A generic version of INVELTYS was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVELTYS?
- What are the global sales for INVELTYS?
- What is Average Wholesale Price for INVELTYS?
Summary for INVELTYS
| International Patents: | 84 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Patent Applications: | 4,390 |
| Drug Prices: | Drug price information for INVELTYS |
| What excipients (inactive ingredients) are in INVELTYS? | INVELTYS excipients list |
| DailyMed Link: | INVELTYS at DailyMed |
Pharmacology for INVELTYS
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for INVELTYS
INVELTYS is protected by thirteen US patents.
Patents protecting INVELTYS
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING OCULAR INFLAMMATION
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INVELTYS
See the table below for patents covering INVELTYS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2871745 | NANOPARTICULES PHARMACEUTIQUES PRESENTANT UN TRANSPORT MUQUEUX AMELIORE (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) | ⤷ Sign Up |
| European Patent Office | 2844223 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2013166436 | ⤷ Sign Up | |
| European Patent Office | 3062796 | ⤷ Sign Up | |
| Australia | 2013256092 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
